Latest Safety News

Kingsgate Consolidated Ltd reported a record September quarter at its Chatree Gold Mine, with gold production surging 18% to nearly 24,000 ounces and silver output exceeding 200,000 ounces. Strong metal prices and operational efficiencies lifted cash and bullion holdings to A$115 million.

Ava Risk Group reported a 5% revenue increase in FY2025, driven by its Detect segment and a strong sales backlog. The company targets over 20% revenue growth in FY2026, supported by its Aura Ai-X fibre optic sensing technology and strategic global partnerships.

Altech Batteries has launched immediate sales of sodium nickel chloride batteries through a strategic collaboration with AMPower, while advancing its flagship CERENERGY project in Germany with strong funding and prototype milestones.

Tanami Gold NL reports significant gold intercepts from ongoing drilling at the Jims Gold Mine, while Mount Gibson Iron moves to acquire Northern Star’s stake in the Central Tanami Project joint venture.

Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.

Terragen Holdings expands its probiotic product range into beef and lamb feedlots, secures key international approvals, and progresses large-scale trials while maintaining a $3 million cash reserve.

Alliance Nickel’s September 2025 quarterly report highlights a robust Definitive Feasibility Study for its NiWest Nickel-Cobalt Project, alongside ongoing strategic partnership talks and solid financial footing.

Kelsian Group reported steady FY25 financial results with a 9.5% revenue increase and reaffirmed FY26 EBITDA guidance, while progressing the strategic divestment of its tourism assets to sharpen focus on core transport services.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.